Clinical efficiency of Elkar at post-hypoxic cardiopathy in infants

The cardiovascular system disease in newborns as a result of antenatal or intranatal hypoxia is an urgent problem. The study goal was to assess the metabolic efficiency of the drug Elkar at the posthypoxic maladjustment syndrome of cardiovascular system in newborns and premature babies. Considering the results of their own research and the relevant medical resources, the authors conclude on high efficiency and safety of Elkar in correction of cardiac disorders in newborns with hypoxic myocardial damage.